Genentech, SU2C Provide Research Funding, Access to 12 Compounds

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

SU2C and Genentech announced a Catalyst collaboration aimed at accelerating the development of new cancer treatments and combination therapies by providing funding and access to a dozen of the company’s medicines.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login